SCHEMBL1620501

SCHEMBL1620501

CCc1nc2c(N3CCOCC3)nc(SCc3ccc(OC)c(NC(=O)CN)c3)nc2n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
TP53 P04637 2/20 0.44
PIK3CA P42336 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
RAB9A P51151 2/20 0.40
HDAC1 Q13547 5/20 0.40
LMNA P02545 3/20 0.40
MAPK1 P28482 1/20 0.40
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
PDE11A Q9HCR9 2/20 0.39
ALDH1A1 P00352 1/20 0.38
PDE3B Q13370 1/20 0.38
AKT1 P31749 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL99386 0.99 TP53 (0.43) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL97899 0.94 MAPT (0.45) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL97115 0.93 TP53 (0.44) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL100419 0.92 TP53 (0.42) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL98839 0.92 MAPT (0.43) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL99288 0.90 GAA (0.42) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL1620566 0.90 PIK3CA (0.42) PIK3CAMEN1KMT2AHDAC1LMNA
SCHEMBL99255 0.90 HDAC1 (0.45) MAPTTP53PIK3CAMEN1KMT2A
SCHEMBL97878 0.89 KMT2A (0.42) MAPTTP53PIK3CAMEN1KMT2A
Hydrochloric Acid SCHEMBL99520 0.88 TP53 (0.43) MAPTTP53PIK3CAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP claimed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME PNP, TYMP, DPYD MAPT 4571/4885TP53 87/4885PIK3CA 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.